Lee et al. [22], in a clinically based cross-sectional study of 320 patients with type 2 diabetes who underwent staging of diabetic nephropathy and evaluated the prognosis of type 2 diabetic nephropathy based on serum creatinine and cystatin C (CysC), found that serum CysC seemed to predict prognosis more accurately than serum creatinine; CysC-based GFR may be more valuable than creatinine-based GFR in predicting the stage of microalbuminuria. The gene discussed is CST3; the disease is type 2 diabetes mellitus.